Department of General Surgery, Chang'an Hospital of Xi'an, Xi'an, China.
Department of Tumor Thoracic Surgery, Hanzhong City People's Hospital, Hanzhong, China.
Ann Palliat Med. 2020 Jul;9(4):2111-2117. doi: 10.21037/apm-20-1224.
The purpose of this study is to evaluate the expression of tumor-specific growth factor (TSGF) and microRNA-214 (miR-214) in the serum of patients with primary hepatocellular carcinoma (PHC) and their predictive values for the curative effect of transcatheter arterial chemoembolization (TACE).
A retrospective analysis of the clinical data of 87 PHC patients were treated with TACE. According to the curative effect 1 month after TACE, PHC patients were divided into disease control group (n=56) and disease progression group (n=31). The expression levels of TSGF and miR-214 were detected by qRT-PCR before or after treatment with TACE in disease control group and disease progression group. The predictive value of TSGF and miR-214 for the efficacy of TACE were evaluated by the receiver operating characteristic (ROC) curve. The Kaplan-Meier survival curve was drawn according to the critical value of ROC. The effect of pretreatment levels of TSGF and miR-214 was analyzed on the three-year survival rate of patients.
After TACE treatment, the mRNA expressive of serum TSGF were increased in progression group, while the levels of miR-214 were decreased compared with control group (P<0.05). Importantly, at one month after TACE treatment, the levels of TSGF were decreased in control group and progression group, while the expression of miR-214 was increased compared with in both groups before TACE treatment(P<0.05). The result of ROC analysis showed that for predicting the curative effect of TACE, the levels of TSGF and miR-214 expression were (181.32, 0.63) (0.849 and 0.807) and (0.759-0.938, 0.707-0.907) in the cutoff values, AUCs and 95% confidence intervals, respectively. The result of Kaplan-Meier analysis showed that the 3-year survival rate of the low TSGF group was up-regulated than that of the high TSGF group [65.12% (31/44) vs. 30.23% (13/43); χ2=5.014; P=0.025]. The 3-year survival rate of the miR-214 high expression group was up-regulated than that of the miR-214 low expression group [61.70% (29/47) vs. 30.00% (12/40); χ2=6.928; P=0.008].
Serum TSGF and miR-214 could be used as potential biomarkers for PHC diagnosis and prognosis.
本研究旨在评估肿瘤特异性生长因子（TSGF）和 microRNA-214（miR-214）在原发性肝细胞癌（PHC）患者血清中的表达及其对经导管动脉化疗栓塞（TACE）疗效的预测价值。
回顾性分析 87 例接受 TACE 治疗的 PHC 患者的临床资料。根据 TACE 后 1 个月的疗效，将 PHC 患者分为疾病控制组（n=56）和疾病进展组（n=31）。采用 qRT-PCR 检测疾病控制组和疾病进展组 TACE 前后 TSGF 和 miR-214 的表达水平。采用受试者工作特征（ROC）曲线评估 TSGF 和 miR-214 对 TACE 疗效的预测价值。根据 ROC 的临界值绘制 Kaplan-Meier 生存曲线。分析预处理 TSGF 和 miR-214 水平对患者 3 年生存率的影响。
TACE 治疗后，进展组血清 TSGF mRNA 表达升高，而 miR-214 水平降低与对照组比较（P<0.05）。重要的是，TACE 治疗后 1 个月，两组 TSGF 水平均降低，而两组 miR-214 表达均高于 TACE 治疗前（P<0.05）。ROC 分析结果表明，预测 TACE 疗效时，TSGF 和 miR-214 表达的截断值分别为（181.32、0.63）、（0.849 和 0.807）和（0.759-0.938、0.707-0.907），AUC 及其 95%置信区间分别为（0.815-0.877）和（0.759-0.877）。Kaplan-Meier 分析结果表明，低 TSGF 组的 3 年生存率高于高 TSGF 组[65.12%（31/44）比 30.23%（13/43）；χ2=5.014；P=0.025]。miR-214 高表达组的 3 年生存率高于 miR-214 低表达组[61.70%（29/47）比 30.00%（12/40）；χ2=6.928；P=0.008]。
血清 TSGF 和 miR-214 可作为 PHC 诊断和预后的潜在生物标志物。
